For the fourth quarter of 2025, consensus estimates for Medline Inc - Class A are pegged at $7.52 billion in revenue and $0.24 in EPS, with the stock currently trading at $49.38, slightly above the $48.00 average analyst price target.
The primary focus for investors is the progress of the company's "Prime Vendor" strategy, specifically the successful conversion of logistics-heavy distribution accounts into higher-margin Medline-branded product sales.
This report is a critical debut for the company, as it represents the first full-year earnings release since its record-breaking $7.2 billion IPO in late 2025. Despite strong volume demand, shareholders are cautious regarding a projected $200 million tariff headwind in 2026 and recent adjusted EBITDA margin compression due to supply chain investments.